Get the Stockscreener App
32.47
1.67%
-0.55
Pre-market:
32.42
-0.05
-0.15%
Tyra Biosciences Inc stock is traded at $32.47, with a volume of 308.52K.
It is down -1.67% in the last 24 hours and down -13.07% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$33.02
Open:
$33.06
24h Volume:
308.52K
Relative Volume:
0.30
Market Cap:
$1.93B
Revenue:
-
Net Income/Loss:
$-119.95M
P/E Ratio:
-16.14
EPS:
-2.0123
Net Cash Flow:
$-95.28M
1W Performance:
-12.34%
1M Performance:
-13.07%
6M Performance:
+53.74%
1Y Performance:
+238.58%
1-Day Range:
$32.16
$33.45
1-Week Range:
$32.16
$37.22
52-Week Range:
$8.75
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
32.47 | 1.96B | 0 | -119.95M | -95.28M | -2.0123 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Guggenheim | Buy |
| Apr-06-26 | Initiated | Canaccord Genuity | Buy |
| Feb-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-21-25 | Resumed | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
TYRA Pulls Back: Market Rotation Hits Communication - Newser
Tyra Biosciences, Inc. Stock 12‑Month Price Target Raised to $51.78, Implies 59% Upside - TradingView
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - Moomoo
Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore - Bez Kabli
Tyra Biosciences (TYRA) Slips Slightly as Stock Holds Between Key Support and Resistance LevelsPro Level Trade Signals - Newser
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY - PR Newswire
Tyra Biosciences (TYRA) Q1 2026 Miss: What Went WrongCommunity Buy Signals - Newser
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Assessing Tyra Biosciences (TYRA) Valuation After Wider Losses And Progress In Dabogratinib Trials - Sahm
Tyra Biosciences (TYRA) Q1 2026 Disappoints — EPS $-0.64 Below $-0.60 ViewsAnalyst Consensus Shift - Newser
TYRA Initiates Coverage On Wolfe Research -- Rating Set to Peer Perform - GuruFocus
Wolfe Research initiates Tyra Biosciences stock at Peerperform By Investing.com - Investing.com Canada
Tyra Biosciences Soars 280% in a Year as HighVista Strategies Boosts StakeSenior Analyst Forecasts - Newser
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares - Yahoo Finance
Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile? - Sahm
(TYRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Commodore Capital (TYRA) reports 2.48M-share, 4.2% stake (Mar 31, 2026) - Stock Titan
Janus Henderson (TYRA) discloses 3.89M shares; 7.2% stake (Schedule 13G/A) - Stock Titan
Canaccord Genuity initiates coverage of Tyra Biosciences (TYRA) with buy recommendation - MSN
Todd Harris reports 2.91M shares in Tyra Biosciences (TYRA) - Stock Titan
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Momentum - Yahoo! Finance Canada
Tyra Biosciences begins dosing in Phase 2 trial for dabogratinib in low grade UTUC - Traders Union
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $45 to $59 - Moomoo
TYRA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
TYRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Tyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings Results - MarketBeat
Hot Picks: Cancer biotech stocks gain ground amid M&A activity - BNN Bloomberg
TYRA: Pivotal data for an oral FGFR3 inhibitor could transform care in NMIBC, UTUC, and achondroplasia - TradingView
Tyra Biosciences Q1 Net Loss Widens - Moomoo
Tyra Biosciences, Inc. Q1 2026 Financial Results and SEC 10-Q Filing Overview - Minichart
Tyra Biosciences Advances Dabogratinib FGFR3 Clinical Trials, Reports Q1 2026 Financial Results and Milestones - Minichart
Tyra Biosciences: Cash, Cash Equivalents and Marketable Securities of $383.5M at 1Q; Runway Into 2H 2028 >TYRA - Moomoo
Tyra Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings Flash (TYRA) Tyra Biosciences Posts Q1 Net Loss $0.64 a Share, vs. FactSet Est of $0.59 Loss - marketscreener.com
Tyra Biosciences 1Q 2026: Net income $(39.3M), EPS $(0.64) — 10-Q Summary - TradingView
Tyra Biosciences (NASDAQ: TYRA) widens Q1 loss but extends cash runway - Stock Titan
Tyra Biosciences reports Q1 2026 net loss $39.3M, cash $383.5M; advances dabogratinib programs - TradingView
[8-K] Tyra Biosciences, Inc. Reports Material Event - Stock Titan
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights - PR Newswire
TYRA (Nasdaq) affiliate sells 8,000 shares on three dates totaling reported proceeds - Stock Titan
Farallon funds disclose multi‑percent TYRA holdings (TYRA) - Stock Titan
TradingKey - TradingKey
Why Tyra Biosciences (TYRA) earnings beat or miss matters less than you think - Newser
Tyra Biosciences earnings on deck as bladder cancer data looms By Investing.com - Investing.com South Africa
Tyra Biosciences earnings on deck as bladder cancer data looms - Investing.com UK
Tyra Biosciences Q4 Loss Widens - Moomoo
Three Tyra Biosciences investor events start May 13, with webcasts - Stock Titan
Tyra Biosciences (NASDAQ: TYRA) CMO awarded RSUs and 85,000-share option - Stock Titan
Tyra Biosciences (TYRA) awards CFO Alan Fuhrman RSUs and 67,000 options - Stock Titan
Tyra Biosciences (NASDAQ: TYRA) CEO receives new RSU and 265,000-share option awards - Stock Titan
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):